Literature DB >> 17172403

Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin.

Wilson S Tsai1, Wen-Shuz Yeow, Alex Chua, Rishindra M Reddy, Duc M Nguyen, David S Schrump, Dao M Nguyen.   

Abstract

Although expressing adequate levels of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors DR4/DR5, significant proportion of cancer cells exhibit resistance to the cytotoxic effect of this ligand. Exposure of Apo2L/TRAIL-refractory cancer cells to cytotoxic chemotherapeutic agents enhances their sensitivity to Apo2L/TRAIL cytotoxicity. This study aims to elucidate the molecular mechanism responsible for the cisplatin-mediated enhancement of Apo2L/TRAIL sensitivity in cultured esophageal cancer cells. Exposure of cancer cells to sublethal concentrations of cisplatin resulted in profound potentiation of their susceptibility to Apo2L/TRAIL cytotoxicity as indicated by 2- to >20-fold reduction in Apo2L/TRAIL IC50 values. Significant activation of caspase-8, caspase-9, and caspase-3 was observed only in cells treated with cisplatin/Apo2L/TRAIL combination and not in those exposed to either agent alone. More importantly, activation of these key caspases was significantly abrogated by overexpression of Bcl2 or by the selective caspase-9 inhibitor. This observation strongly suggested that caspase-8 activation in cells treated with the cisplatin/Apo2L/TRAIL combination was secondary to the mitochondria-mediated amplification feedback loop and activation of the executioner caspase-3 was dependent on the recruitment of the intrinsic pathway characteristic of the type II cell. Profound combination-mediated cytotoxicity and induction of apoptosis was completely suppressed either by Bcl2 overexpression or by inhibition of caspase-9 activity, which conclusively pointed to the essential role of the mitochondria-dependent death signaling cascade in this process. Cisplatin sensitizes esophageal cancer cells to Apo2L/TRAIL cytotoxicity by potentiation of the mitochondria-dependent death signaling pathway that leads to amplification of caspase activation, particularly caspase-8, by the feedback loop to efficiently induce apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17172403     DOI: 10.1158/1535-7163.MCT-05-0514

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  13 in total

1.  TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.

Authors:  Suizhao Wang; Wenhong Ren; Jeffery Liu; Guy Lahat; Keila Torres; Gonzalo Lopez; Alexander J Lazar; Andrea Hayes-Jordan; Kebin Liu; Jim Bankson; John D Hazle; Dina Lev
Journal:  Clin Cancer Res       Date:  2010-04-20       Impact factor: 12.531

2.  Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.

Authors:  Naoko Seki; Uhi Toh; Thomas J Sayers; Teruhiko Fujii; Motoshi Miyagi; Yoshito Akagi; Jingo Kusukawa; Masayoshi Kage; Kazuo Shirouzu; Hideaki Yamana
Journal:  Mol Cancer Ther       Date:  2010-06-01       Impact factor: 6.261

3.  Dual role of ERK2/NF-κB signaling in TRAIL sensitivity.

Authors:  Myoung Woo Lee; Dae Seong Kim; Ji Eun Eom; Ji Won Lee; Ki Woong Sung; Hong Hoe Koo; Young Bin Hong; Keon Hee Yoo
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

4.  Macrophage Apoptosis Triggered by IpaD from Shigella flexneri.

Authors:  Olivia Arizmendi; William D Picking; Wendy L Picking
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

5.  Overexpression of cyclin B1 antagonizes chemotherapeutic-induced apoptosis through PTEN/Akt pathway in human esophageal squamous cell carcinoma cells.

Authors:  Yunwei Ou; Liying Ma; Ling Ma; Zhen Huang; Wei Zhou; Chunling Zhao; Bailin Zhang; Yongmei Song; Chunjiang Yu; Qimin Zhan
Journal:  Cancer Biol Ther       Date:  2012-10-31       Impact factor: 4.742

6.  Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer.

Authors:  Shengpeng Wang; Min Shao; Zhangfeng Zhong; Anqi Wang; Jiliang Cao; Yucong Lu; Yitao Wang; Jinming Zhang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

7.  Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance.

Authors:  Jesús García-Cano; Gorbatchev Ambroise; Raquel Pascual-Serra; Maria Carmen Carrión; Leticia Serrano-Oviedo; Marta Ortega-Muelas; Francisco J Cimas; Sebastià Sabater; María José Ruiz-Hidalgo; Isabel Sanchez Perez; Antonio Mas; Félix A Jalón; Aimé Vazquez; Ricardo Sánchez-Prieto
Journal:  Oncotarget       Date:  2015-06-20

8.  TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma.

Authors:  Adrien Daigeler; Christina Brenzel; Daniel Bulut; Anne Geisler; Christoph Hilgert; Marcus Lehnhardt; Hans U Steinau; Annegret Flier; Lars Steinstraesser; Ludger Klein-Hitpass; Ulrich Mittelkötter; Waldemar Uhl; Ansgar M Chromik
Journal:  J Exp Clin Cancer Res       Date:  2008-12-12

9.  Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism.

Authors:  Alois Kozubík; Alena Vaculová; Karel Soucek; Jan Vondrácek; Jaroslav Turánek; Jirina Hofmanová
Journal:  Met Based Drugs       Date:  2008

10.  Ethanolic Neem (Azadirachta indica) Leaf Extract Prevents Growth of MCF-7 and HeLa Cells and Potentiates the Therapeutic Index of Cisplatin.

Authors:  Chhavi Sharma; Andrea J Vas; Payal Goala; Taher M Gheewala; Tahir A Rizvi; Arif Hussain
Journal:  J Oncol       Date:  2014-01-30       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.